Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05821478 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients

Study acronym: ABCESS2
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruitingv4 Show 4 more changesShow less
    • Primary completion date: Dec 15, 2025 to Feb 28, 2027
    • Start date changed from estimate of Apr 15, 2024 to May 22, 2025
    • Study sites: 5 to 4
    • Study completion date: Sep 15, 2026 to Feb 27, 2028
  2. Primary completion date: Feb 15, 2025 to Dec 15, 2025
    • Start date: Nov 15, 2023 to Apr 15, 2024
    • Study completion date: Feb 15, 2026 to Sep 15, 2026
    v3
  3. Start date: Aug 1, 2023 to Nov 15, 2023v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study evaluates the efficacy of an adapted antibiotherapy in Hurley stage 2 active Hidradenitis Suppurativa patients versus tetracycline derivative
Trial Details
NCT Number NCT05821478
Lead Sponsor Institut Pasteur
Collaborators: Centre Hospitalier Universitaire de Caen, Hôpital Necker-Enfants Malades, Ministry of Health, France, Assistance Publique Hopitaux De Marseille
Conditions
(from sponsor)		 Hidradenitis Suppurativa
Related terms Hidradenitis Suppurativa
Enrollment 92 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov